Immuno-Oncology | Specialty

Emerging Vaccines in Glioblastoma

December 21st 2016

Glioblastoma: The Potential Role of Immunotherapy

December 21st 2016

Overcoming Challenges in Glioblastoma

December 21st 2016

Glioblastoma: Educating Patients on Tumor-Treating Field Therapy

December 21st 2016

Practical Experience With Optune in Glioblastoma

December 21st 2016

Tumor-Treating Field Therapy in Glioblastoma: Patient Selection

December 21st 2016

New Long-term Data for Tumor-Treating Fields in Glioblastoma

December 21st 2016

Glioblastoma: Impact of Tumor-Treating Field Therapy

December 21st 2016

The Role of Chemoradiotherapy in Glioblastoma

December 21st 2016

Glioblastoma: Guideline Recommendations for Treatment

December 21st 2016

Classification and Prognosis of Glioblastoma

December 21st 2016

Glioblastoma: The Role of Resection

December 21st 2016

Multidisciplinary Care in Glioblastoma

December 21st 2016

What is Glioblastoma?

December 21st 2016

Dr. Pavlick on Immunotherapy Clinical Trials in Basal and Squamous Cell Carcinomas

December 20th 2016

Anna C. Pavlick, DO, medical oncologist, NYU Langone School of Medicine, discusses ongoing clinical trials exploring treatment with immunotherapy in patients with basal cell carcinoma as well as squamous cell carcinoma.

Dr. de Souza on Next Steps for Immunotherapy in Head and Neck Cancer

December 20th 2016

Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.

Dr. Luke on Challenges With Immunotherapy in Melanoma

December 20th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses some of the challenges that oncologists may face when administering immunotherapy agents to patients with melanoma.

New Breed of Denials Is a Test of Fortitude

December 17th 2016

Many things are happening with payer practices as a result of the plethora of new immuno-oncology agents.

Frontline Pembrolizumab Receives Positive CHMP Opinion for PD-L1+ NSCLC

December 17th 2016

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of frontline pembrolizumab for the treatment of patients with metastatic non–small cell lung cancer whose tumors do not harbor EGFR or ALK mutations.

Stefani Spranger on Checkpoint Blockade Therapies in Melanoma

December 16th 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses immune checkpoint blockade therapies that are currently being used to treat patients with melanoma.